Agios Pharmaceuticals (AGIO) Operating Leases (2019 - 2026)

Agios Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $16.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 68.0% year-over-year to $16.9 million; the trailing twelve-month figure through Mar 2026 stood at $16.9 million (down 68.0% YoY), and the FY2025 full-year result was $21.8 million, down 45.74% from the prior year.
• Operating Leases for Q1 2026 stood at $16.9 million, down from $21.8 million in the prior quarter.
• The five-year high for Operating Leases was $94.1 million in Q1 2022, with the low at $16.9 million in Q1 2026.
• Historically, Operating Leases has averaged $58.6 million across 5 years, with a median of $64.6 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Leases climbed 0.0% — and 2026, when it slumped 68.0%.
• Agios Pharmaceuticals' Operating Leases stood at $72.0 million in 2022, then slipped by 20.85% to $57.0 million in 2023, then retreated by 29.45% to $40.2 million in 2024, then plunged by 45.74% to $21.8 million in 2025, then declined by 22.35% to $16.9 million in 2026.
• The last three Operating Leases figures came in at $16.9 million (Q1 2026), $21.8 million (Q4 2025), and $26.5 million (Q3 2025), per Business Quant data.